Patent application number | Description | Published |
20090035232 | FIXED-DOSE ASSOCIATION OF PHYTATE AND ZINC - The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallisation of hydroxyapatite in humans. | 02-05-2009 |
20110172194 | COMPOSITION OF DIALYSIS LIQUID COMPRISING CRYSTALLISATION INHIBITOR SUBSTANCES - This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation. | 07-14-2011 |
20130032494 | PORTABLE DEVICE FOR ANALYSING pH OR ANOTHER VARIABLE BY ELECTROCHEMICAL MEASUREMENT - Portable device ( | 02-07-2013 |
20140056994 | Fixed-Dose Association of Phytate and Zinc - The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans. | 02-27-2014 |
20140302166 | COMPOSITION OF DIALYSIS LIQUID COMPRISING CRYSTALLISATION INHIBITOR SUBSTANCES - This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation. | 10-09-2014 |
20150374752 | COMPOSITION OF DIALYSIS LIQUID COMPRISING CRYSTALLISATION INHIBITOR SUBSTANCES - This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation. | 12-31-2015 |
20160061813 | PORTABLE DEVICE FOR ANALYSING pH OR ANOTHER VARIABLE BY ELECTROCHEMICAL MEASUREMENT - Portable device ( | 03-03-2016 |